Журнал микробиологии, эпидемиологии и иммунобиологии (Dec 2018)

PRECLINICAL STUDIES OF RECOMBINANT PSEUDOMONAS VACCINE

  • N. A. Mihailova,
  • A. A. Kaloshin,
  • E. M. Zimina,
  • A. V. Soldatenkova,
  • A. V. Poddubikov

DOI
https://doi.org/10.36233/0372-9311-2018-6-31-37
Journal volume & issue
Vol. 0, no. 6
pp. 31 – 37

Abstract

Read online

Aim. Evaluation of the efficacy and safety of the three experimental lots of Recombinant Pseudomonas Vaccine. Materials and methods. The preparation contained the recombinant proteins OprF and toxoid that were purified by chromatography in nickel-sepharose. Aluminum hydroxide was used as an adjuvant. The authenticity of the vaccine components was confirmed by electrophoresis and immunoblotting. The concentration of endotoxin in the vaccine was determined by LAL test. The abnormal toxicity was evaluated in mice and cavy. The anaphylactic activity was evaluated in cavy. The delayed-type hypersensitivity reaction was evaluated in mice. Evaluation of the immunogenicity was carried out in an experiment with on double immunization of mice with following intraperitoneally infection by a live virulent culture of P. aeruginosa (PA-103 strain). Results. The authenticity of the vaccine, sterility, non-pyrogenicity and non-toxicity were confirmed after the studying of the quality indicators of the three lots of Recombinant Pseudomonas Vaccine. In animal experiments, the vaccine did not possess allergic properties and it was shown that it protected mice against Pseudomonas infection with Index of efficiency 3.0 and more. Conclusion. The efficacy, the safety, and the standardization of three experimental lots of the recombinant vaccine, which is intended to prevent infections caused by P. aeruginosa, have been shown.

Keywords